悦康药业：注射用YKYY031获药物临床试验批准通知书

Core Viewpoint - Yuyuan Pharmaceutical (688658) announced that its wholly-owned subsidiary, Beijing Yuyuan Kete Pharmaceutical Technology Co., Ltd., and Hangzhou Tianlong Pharmaceutical Co., Ltd. have recently received approval from the National Medical Products Administration for the clinical trial of injectable YKYY031 for advanced solid tumors [1] Group 1 - Yuyuan Pharmaceutical's subsidiary has obtained a clinical trial approval for YKYY031 [1] - The approval is specifically for the treatment of advanced solid tumors [1]